- Email:
Striatal Neuron Differentiation Service
Introduction
Striatal Neuron Differentiation directs pluripotent stem cells to differentiate into Medium Spiny Neurons (MSNs) by simulating ventral forebrain development. MSNs account for 95% of striatal neurons and are the main target cells in Huntington's disease. Human-specific regulators are critical for studying disease progression.
Our service generates high-purity MSN models via the NeuroST platform and Dual SMAD inhibition. It provides stable, mature neurons with consistent quality and key markers. Patient-derived iPSC lines are available to support research on pathological phenotypes and accelerate neurodegenerative drug discovery.
Discover How We Can Help - Request a Consultation
Striatal Neuron Differentiation Service
Striatal medium spiny neurons (MSNs) represent the predominant neuronal population in the striatum, governing motor control, reward processing, and habit formation. Degeneration and dysfunction of MSNs are the pathological hallmarks of Huntington's disease and are closely related to Parkinsonism, dystonia, and other neuropsychiatric disorders.
Key Features
- Derived from human iPSCs/ESCs under defined, xeno-free, and feeder-free conditions
- Uses dual SMAD inhibition and ventral forebrain patterning for highly efficient MSN specification
- Generates mature DARPP-32+ and CTIP2+ medium spiny neurons with high purity
- Stable expression of striatal-enriched markers, including RGS4, FOXP1, and GABA
- Produces functionally mature GABAergic striatal neurons with physiological activity
Service Content
- Induction and expansion of striatal neural progenitors
- Directed differentiation into mature striatal medium spiny neurons
- Long-term maturation and functional stabilization in vitro
- Quality validation: immunofluorescence staining, qPCR, Western blot, calcium imaging
- Optional: patch-clamp electrophysiology, co-culture systems, patient iPSC-based models
Related Diseases & Mechanisms
| Disease | Mechanism Involving Striatal Neurons |
|---|---|
| Huntington's Disease | Progressive MSN degeneration, mHTT aggregation, synaptic dysfunction |
| Parkinson's Disease | Imbalanced striatal dopaminergic input and motor circuit dysregulation |
| Dystonia | Abnormal striatal output and motor inhibitory signaling |
| Drug Addiction | Dysregulation of striatal reward and motivation circuits |
| Neuropsychiatric Disorders | Striatal GABAergic dysfunction and circuit imbalance |
Applications
- Disease modeling for striatal degeneration and neuropsychiatric disorders
- High-throughput drug screening and efficacy evaluation
- Mechanistic studies of neuronal death, synaptic dysfunction, and circuit disorders
- Toxicity testing and target validation for neurodegenerative drug discovery
Workflow
Our structured workflow is designed for maximum transparency and scientific rigor, ensuring that every batch of neurons meets the exacting standards of high-throughput drug screening.
What We Can Offer
Creative Biolabs provides an industry-leading suite of solutions for Striatal Neuron Differentiation, ranging from initial cellular reprogramming to large-scale industrial applications. Our customized services are designed to meet the unique physiological requirements of your research.
One-stop differentiation service
from laboratory-scale validation to high-volume pilot production for drug screening.
Efficient upstream and downstream process development
optimizing neural precursor expansion and subsequent MSN maturation.
Scalable industrial-grade neural culture systems
capable of producing large cell volumes (up to 109 neurons) to support high-throughput screening (HTS) campaigns.
Custom Genetic Engineering
including CRISPR/Cas9-mediated gene knockout or knock-in (e.g., RGS4 stabilization or mutant HTT insertion) to create bespoke disease models.
Well-established quality system
utilizing Quality-by-Design (QbD) and process analytical techniques (PAT) to ensure batch-to-batch consistency.
Guaranteed stability of cell banks
ensuring that iPSC-derived progenitors maintain their differentiation potential across multiple passages.
High-standard quality control tools
including single-cell RNA sequencing (scRNA-seq) and MEA recordings to quantify and evaluate product purity and maturity.
Experience the Creative Biolabs Advantage - Get a Quote Today
Case Study
FAQs
Q1: What purity level can be achieved for your striatal neurons, and which key markers are applied for validation?
A: Our differentiated striatal neurons consistently achieve a purity of over 85%, with robust validation for canonical markers including DARPP-32, CTIP2, GABA, and FOXP1. Full characterization data from immunofluorescence, qPCR, and Western blot are included in the final deliverables.
Q2: How long is the full differentiation process for striatal neurons, and what is the standard turnaround time for the service?
A: The entire workflow from pluripotent stem cells to mature and functional striatal neurons takes approximately 45-60 days. The total service turnaround time from order confirmation to final delivery is typically 8-10 weeks.
Q3: Do you accept customer-supplied iPSC lines for striatal neuron differentiation?
A: Yes, we support differentiation services using client-provided iPSC lines. In addition, we offer validated Huntington's disease patient-specific iPSC lines for accurate disease modeling.
Q4: Do you provide functional characterization assays such as electrophysiology or synaptic activity analysis?
A: Yes, we offer full-scale functional assessments, including calcium imaging and whole-cell patch-clamp recording, to confirm neuronal activity. We also perform specialized analyses for synaptic function and RGS4-mediated neuronal excitability.
Creative Biolabs offers a suite of services for the differentiation, characterization, and application of striatal neurons. From custom CRISPR engineering to large-scale HTS support, we provide the tools necessary to unlock the complexities of the basal ganglia.
Contact Our Team for More Information and to Discuss Your Project
For Research Use Only. Not For Clinical Use.